Teva Wants Strict FDA Review For Biogen's Rival MS Drug

Law360, New York (January 10, 2013, 4:27 PM EST) -- Teva Pharmaceutical Industries Ltd. is imploring the U.S. Food and Drug Administration not to approve any new multiple sclerosis drugs without first consulting an advisory committee of independent experts, a move aimed at delaying a rival product from Biogen Idec Inc.

The drugmaker's Dec. 31 citizen petition to the FDA argued that although review by the agency's Peripheral and Central Nervous System Drugs Advisory Committee is not required, Congress has strongly suggested such panels should examine new medicines prior to approval unless there's a compelling reason...
To view the full article, register now.